MicroSectors FANG and Innovation 3X Leveraged ETN vs Viatris Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.82 (market cap $2.98B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 6.7× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and Viatris Inc pays a 2.75% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Viatris Inc for 57 Days on average.
| FNGU | VTRS | |
|---|---|---|
Market Cap | $2.98B | $20.03B |
Volume | 4,682,352 | 14,109,977 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $18.27 |
52-Week Low | $13.73 | $9.74 |
Typical Hold Time | 19 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $35.99, down 3.25% today. Technical indicators show a bullish trend with strong moving average support but neutral oscillators. The ETN faces significant volatility risks as highlighted by recent analysis showing it lost 87% during previous tech sector downturns. Support levels cluster around $33-35 with resistance at $37-39.
While leveraged exposure to AI leaders like Nvidia and Meta offers upside potential during tech rallies, the extreme volatility and historical drawdowns present substantial risk. Investors should weigh the potential for amplified returns against the documented vulnerability to sector corrections, requiring careful risk management in portfolio allocation.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →